Targeting of PNKP was previously proposed to have a therapeutic potential in several human cancers, including lung, breast, colorectal, and prostate cancer, particularly in combination with γ-radiation or topoisomerase I inhibitor [62,63]. This evidence concerns the gene PNKP and Familial prostate cancer.